Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 8/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GRK2 | P25098 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26286575 | 0.93 | PDK2 (0.41) | PDK2GSK3BDRD2DRD3DRD4 | |
| SCHEMBL20175199 | 0.93 | PDK2 (0.41) | PDK2GSK3BDRD2DRD3DRD4 | |
| SCHEMBL18804886 | 0.80 | PDK2 (0.51) | PDK2OPRM1OPRD1MEN1KMT2A | |
| SCHEMBL20199300 | 0.80 | PDK2 (0.46) | PDK2GSK3BDRD2DRD3DRD4 | |
| SCHEMBL18118801 | 0.79 | ALOX5 (0.46) | PDK2NMUR2OPRM1OPRD1MEN1 | |
| SCHEMBL19395170 | 0.79 | PDK2 (0.45) | PDK2NMUR2OPRM1OPRD1MEN1 | |
| SCHEMBL16232654 | 0.79 | ALOX5 (0.52) | PDK2NMUR2OPRM1OPRD1MEN1 | |
| SCHEMBL19395178 | 0.79 | PDK2 (0.45) | PDK2NMUR2OPRM1OPRD1MEN1 | |
| SCHEMBL16232652 | 0.79 | ALOX5 (0.52) | PDK2NMUR2OPRM1OPRD1MEN1 | |
| SCHEMBL19395171 | 0.78 | ALOX5 (0.51) | PDK2NMUR2OPRM1OPRD1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148639-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-31 | — | — | US | disclosed |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, NR2E3, ERG | PDK2 651/4885GSK3B 3881/4885DRD2 804/4885 |
| US-20180148639-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, NR2E3, ERG | PDK2 651/4885GSK3B 3881/4885DRD2 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.